Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells

European Journal of Medicinal Chemistry

Volumn 121, Issue , 2016, Pages 58-70

  Kulabaş, Necla ^a   Tatar, Esra ^a   Bingöl Özakpınar, Özlem ^a   Özsavcı, Derya ^a   Pannecouque, Christophe ^b   De Clercq, Erik ^b   Küçükgüzel, İlkay ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

1,2,4 Triazoles; Anticancer activity; Apoptosis; Bcl 2; Caspase 3; Caspase 8; Thioethers

Indexed keywords

2 [[3 [[4 (ACETYLAMINO)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL] N (4 BROMOPHENYL)ACETAMIDE; 2 [[3 [[4 (ACETYLAMINO)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [[3 [[4 (ACETYLAMINO)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL] N (4 SULFAMOYLPHENYL)ACETAMIDE; 2 [[3 [[4 (ACETYLAMINO)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4-TRIAZOL 5 YL] SULFANYL] N (4 NITROPHENYL)ACETAMIDE; 2 [[3 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]METHYL] 4 BENZY 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL]SULFANYL] N (4 SULFAMOYLPHGENYL) ACETAMIDE; 2 [[3 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [[3 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL] N (4 NITROPHENYL)ACETAMIDE; 2 [[3 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL]SULFANYL] N (4 BROMOPHENYL)ACETAMIDE; 2 [[4 BENZYL 5 [(NAPHTHALEN 2 YLOXY)METHYL] 4H 1,2,4 TRIAZOL 3 YL]SULFANYL] N (4 BROMOPHENYL)ACETAMIDE; 2 [[4 BENZYL 5 [(NAPHTHALEN 2 YLOXY)METHYL] 4H 1,2,4 TRIAZOL 3 YL]SULFANYL] N (4 NITROPHENYL)ACETAMIDE; 2 [[4 BENZYL 5 [(NAPHTHALEN 2 YLOXY)METHYL] 4H 1,2,4TRIAZOL 3 YL]SULFANYL] N (4 CHLOROPHENYL)ACETAMIDE; 2 [[4 BENZYL 5 [(NAPHTHALEN-2-YLOXY)METHYL] 4H 1,2,4 TRIAZOL 3 YL]SULFANYL] N (4 SULFAMOYLPHENYL)ACETAMIDE; 4 BENZYL 5 [(NAPHTHALEN 2 YLOXY)METHYL] 2,4 DIHYDRO 3H 1,2,4 TRIAZOLE 3 THIONE; 4 [[[[4 BENZYL 5 [(NAPHTHALEN 2 YLOXY)METHYL] 4H 1,2,4 TRIAZOL 3 YL]SULFANYL]ACETYL]AMINO]BENZOATE; ACETAMIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; ETHYL 4 [[[[3 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]METHYL] 4 BENZYL 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 5 YL] SULFANYL]ACETY])AMINO]BENZOATE; N BENZYL 2 [(NAPHTHALEN 2 YLOXY)ACETYL]HYDRAZINECARBOTHIOAMIDE; N BENZYL 2 [[5 METHYL 2 (PROPAN 2 YL)PHENOXY]ACETYL] HYDRAZINECARBOTHIOAMIDE; N [4 [(4 BENZYL 5 THIOXO 4,5 DIHYDRO 1H 1,2,4 TRIAZOL 3 YL) METHOXY]PHENYL]ACETAMIDE; N [4 [2 [2 (BENZYLCARBAMOTHIOYL)HYDRAZINYL] 2 OXOETHOXY] PHENYL]ACETAMIDE; PROTEIN BCL 2; UNCLASSIFIED DRUG; 1,2,4-TRIAZOLE; APOPTOSIS REGULATORY PROTEIN; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL VIABILITY ASSAY; CYTOTOXICITY ASSAY; DRUG SCREENING; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; LEUKEMIA CELL LINE; LUNG CANCER CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ACETAMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 84981298693     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.05.017     Document Type: Article

References (62)

1. [1] Kamel, M.M., Megally Abdo, N.Y., Eur. J. Med. Chem. 86 (2014), 75–80.
2. [2] Khazir, J., Hyder, I., Gayatri, J.L., Prasad Yandrati, L., Nalla, N., Chasoo, G., Mahajan, A., Saxena, A.K., Alam, M.S., Qazi, G.N., Sampath Kumar, H.M., Eur. J. Med. Chem. 82 (2014), 255–262.
3. [3] Oh, J.-K., Weiderpass, E., Ann. Glob. Health 80 (2014), 384–392.
4. [4] Brugnaro, P., Morelli, E., Cattelan, F., Petrucci, A., Panese, S., Eseme, F., Cavinato, F., Barelli, A., Raise, E., World J. Virol. 4 (2015), 209–218.
5. [5] Fares, M., Abou-Seri, S.M., Abdel-Aziz, H.A., Abbas, S.E.-S., Youssef, M.M., Eladwy, R.A., Eur. J. Med. Chem. 83 (2014), 155–166.
6. [6] Wan, Y., Wu, S., Xiao, G., Liu, T., Hou, X., Chen, C., Guan, P., Yang, X., Fang, H., Bioorg. Med. Chem. 23 (2015), 1994–2003.
7. [7] Corredor, M., Bujons, J., Orzáez, M., Sancho, M., Pérez-Payá, E., Alfonso, I., Messeguer, A., Eur. J. Med. Chem. 63 (2013), 892–896.
8. [8] Gamal-Eldeen, A.M., Hamdy, N.A., Abdel-Aziz, H.A., El-Hussieny, E.A., Fakhr, I.M.I., Eur. J. Med. Chem. 77 (2014), 323–333.
9. [9] Elmore, S., Toxicol. Pathol. 35 (2007), 495–516.
10. [10] Önen-Bayram, F.E., Durmaz, I., Scherman, D., Herscovici, J., Cetin-Atalay, R., Bioorg. Med. Chem. 20 (2012), 5094–5102.
11. [11] Zhou, C.-H., Wang, Y., Curr. Med. Chem. 19 (2012), 239–280.
12. [12] Küçükgüzel, Ş.G., Çıkla-Süzgün, P., Eur. J. Med. Chem. 97 (2015), 830–870.
13. [13] Jubie, S., Prabitha, P., Rajesh Kumar, R., Kalirajan, R., Gayathri, R., Sankar, S., Elango, K., Med. Chem. Res. 21 (2012), 1403–1410.
14. [14] Küçükgüzel, İ., Küçükgüzel, S.G., Rollas, S., Kiraz, M., Bioorg. Med. Chem. Lett. 11 (2001), 1703–1707.
15. [15] Küçükgüzel, Ş.G., Küçükgüzel, İ., Tatar, E., Rollas, S., Sahin, F., Gulluce, M., De Clercq, E., Kabasakal, L., Eur. J. Med. Chem. 42 (2007), 893–901.
16. [16] Çıkla-Süzgün, P., Kaushik-Basu, N., Basu, A., Arora, P., Talele, T.T., Durmaz, I., Çetin-Atalay, R., Küçükgüzel, Ş.G., J. Enzyme Inhib. Med. Chem. 30 (2015), 778–785.
17. [17] Sztanke, K., Tuzimski, T., Rzymowska, J., Pasternak, K., Kandefer-Szerszen, M., Eur. J. Med. Chem. 43 (2008), 404–419.
18. [18] Orek, C., Koparır, P., Koparır, M., Spectrochim. Acta Mol. Biomol. Spectrosc. 97 (2012), 923–934.
19. [19] Zhao, P.L., Ma, W.F., Duan, A.N., Zou, M., Yan, Y.C., You, W.W., Wu, S.G., Eur. J. Med. Chem. 54 (2012), 813–822.
20. [20] Hou, Y.P., Sun, J., Pang, Z.H., Lv, P.C., Li, D.D., Yan, L., Zhang, H.J., Zheng, E.X., Zhao, J., Zhu, H.L., Eur. J. Med. Chem. 19 (2011), 5948–5954.
21. [21] Puthiyapurayil, P., Poojary, B., Chikkanna, C., Buridipad, S.K., Eur. J. Med. Chem. 57 (2012), 407–416.
22. [22] Takahashi, K., Yamagishi, G., Hiramatsu, T., Hosoya, A., Onoe, K., Doi, H., Nagata, H., Wada, Y., Onoe, H., Watanabe, Y., Hosoya, T., Bioorg. Med. Chem. 19 (2011), 1464–1470.
23. [23] De La Rosa, M., Kim, H.W., Gunic, E., Jenket, C., Boyle, U., Koh, Y.H., Korboukh, I., Allan, M., Zhang, W., Chen, H., Xu, W., Nilar, S., Yao, N., Hamatake, R., Lang, S.A., Hong, Z., Zhang, Z., Girardet, J.L., Bioorg. Med. Chem. Lett. 16 (2006), 4444–4449.
24. [24] Wang, Z., Wu, B., Kuhen, K.L., Bursulaya, B., Nguyen, T.N., Nguyen, D.G., He, Y., Bioorg. Med. Chem. Lett. 16 (2006), 4174–4177.
25. [25] Özkay, Y., İncesu, Z., Önder, N.I., Tunalı, Y., Karaca, H., Işıkdağ, I., Uçucu, U., Med. Chem. Res. 22 (2013), 211–218.
26. [26] Özkay, Y., Işıkdağ, İ., İncesu, Z., Akalın, G., Eur. J. Med. Chem. 45 (2010), 3320–3328.
27. [27] Reddy, T.R.K., Li, C., Guo, X., Fischer, P.M., Dekker, L.V., Bioorg. Med. Chem. 22 (2014), 5378–5391.
28. [28] Ed. Geistlich Soehne. (1974). Patent: DE2357591.
29. [29] Baraldi, P.G., Preti, D., Tabrizi, M.A., Fruttarolo, F., Saponaro, G., Baraldi, S., Romagnoli, R., Moorman, A.R., Gessi, S., Varani, K., Borea, P.A., Bioorg. Med. Chem. 15 (2007), 2514–2527.
30. [30] Pohloudek-Fabini, R., Schroepl, E., Pharmazie 23 (1968), 561–566.
31. [31] Smithkline Beecham Corporation. (2007). Patent: WO2007/18941.
32. [32] Murza, M.M., Safarov, M.G., Russ. J. Org. Chem. 36 (2000), 1201–1203.
33. [33] Küçükgüzel, İ., Tatar, E., Küçükgüzel, Ş.G., Rollas, S., De Clercq, E., Eur. J. Med. Chem. 43 (2008), 381–392.
34. [34] Tian, B., He, M., Tan, Z., Tang, S., Hewlett, I., Chen, S., Jin, Y., Yang, M., Chem. Biol. Drug. Des. 77 (2011), 189–198.
35. [35] Roda, K.P., Vansdadia, R.N., Parekh, H., J. Indian Chem. Soc. 63 (1986), 594–595.
36. [36] Nargund, L.V.G., Reddy, G.R.N., Hariprasad, V., J. Pharm. Sci. 83 (1994), 246–248.
37. [37] Küçükgüzel, Ş.G., Oruç, E.E., Rollas, S., Şahin, F., Özbek, A., Eur. J. Med. Chem. 37 (2002), 197–206.
38. [38] Salgın-Gökşen, U., Gökhan-Kelekçi, N., Göktaş, Ö., Köysal, Y., Kılıç, E., Işık, Ş., Aktay, G., Özalp, M., Bioorg. Med. Chem. 15 (2007), 5738–5751.
39. [39] Küçükgüzel, Ş.G., Kocatepe, A., De Clercq, E., Şahin, F., Güllüce, M., Eur. J. Med. Chem. 41 (2006), 353–359.
40. [40] Tatar, E., Küçükgüzel, İ., De Clercq, E., Krishnan, R., Kaushik-Basu, N., Marmara Pharm. J. 16 (2012), 181–193.
41. [41] Kumar, H., Javed, S.A., Khan, S.A., Amir, M., Eur. J. Med. Chem. 43 (2008), 2688–2698.
42. [42] Palaska, E., Şahin, G., Kelicen, P., Durlu, N.T., Altinok, G., Il Farmaco 57 (2002), 101–108.
43. [43] Yurttaş, L., Özkay, Y., Akalın-Çiftçi, G., Ulusoylar-Yıldırım, Ş., J. Enzyme Inhib. Med. Chem. 29 (2014), 175–184.
44. [44] Pannecouque, C., Daelemans, D., De Clercq, E., Nat. Protoc. 3 (2008), 427–434.
45. [45] Boyd, M.R., Paull, K.D., Drug. Dev. Res. 34 (1995), 91–109.
46. [46] Alley, M.C., Scudiero, D.A., Monks, A., Hursey, M.L., Czerwinski, M.J., Fine, D.L., Abbott, B.J., Mayo, J.G., Shoemaker, R.H., Boyd, M.R., Cancer Res. 48 (1988), 589–601.
47. [47] Grever, M.R., Schepartz, S.A., Chabner, B.A., Semin. Oncol. 19 (1992), 622–638.
48. [48] Monks, A.P., Scudiero, D.A., Shekan, P., Shoemaker, K.D., Paull, D., Vistica, C., Hose, C., Langley, J., Cronise, P., Vaigro–Wolff, A., Gray-Goodrich, M., Cambell, H., Mayo, M., Boyd, M., J. Natl. Cancer Inst. 83 (1991), 757–766.
49. [49] Shoemaker, R.H., Nat. Rev. Cancer 6 (2006), 813–823.
50. [50] Çıkla, P., Özsavcı, D., Bingöl-Özakpınar, Ö., Şener, A., Çevik, Ö., Özbaş-Turan, S., Akbuğa, J., Şahin, F., Küçükgüzel, Ş.G., Arch. Pharm. (Weinh.) 346 (2013), 367–379.
51. [51] Ballot, C., Kluza, J., Martoriati, A., Nyman, U., Formstecher, P., Joseph, B., Bailly, C., Marchetti, P., Mol. Cancer Ther. 8 (2009), 3307–3317.
52. [52] Berthold, D.R., Pond, G.R., Soban, F., De, W.R., Eisenberger, M., Tannock, I.F., J. Clin. Oncol. 26 (2008), 242–245.
53. [53] Haldar, S., Basu, A., Croce, C.M., Cancer Res. 57 (1997), 229–233.
54. [54] Varol, U., Degirmenci, M., Karaca, B., Atmaca, H., Kisim, A., Uzunoglu, S., Sezgin, C., Sanli, U.A., Uslu, R., Tumour Biol. 36 (2015), 779–786.
55. [55] Küçükgüzel, Ş.G., Koç, D., Çıkla-Süzgün, P., Özsavcı, D., Bingöl-Özakpınar, Ö., Mega-Tiber, P., Orun, O., Erzincan, P., Sağ-Erdem, S., Şahin, F., Arch. Pharm. (Weinh.) 348 (2015), 730–742.
56. [56] Gu, Q., Wang, J.D., Xia, H.H.X., Lin, M.C.M., He, H., Zou, B., Tu, S.P., Yang, Y., Liu, X.G., Lam, S.K., Wong, W.M., Chan, A.O.O., Yuen, M.F., Kung, H.F., Chun-Yu Wong, B., Carcinogenesis 26 (2005), 541–546.
57. [57] Banerjee, P., Majumder, P., Halder, S., Drew, M.G., Bhattacharya, S., Mazumder, S., Free Radic. Res. 49 (2015), 253–268.
58. [58] Baran, Y., Zencir, S., Çakır, Z., Öztürk, E., Topçu, Z.J., Clin. Pharm. Ther. 36 (2011), 673–679.
59. [59] Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., J. Virol. Methods 20 (1988), 309–321.
60. [60] Popovic, M., Sarngadharan, M.G., Read, E., Gallo, R.C., Science 224 (1984), 497–500.
61. [61] Barré-Sinoussi, F., Chermann, J.C., Nugeyre, M.T., Chamaret, S., Grest, J., Dauget, C., Axler-Blin, C., Vézinet-Brun, F., Rouzioux, C., Rozenbaum, W., Montagnier, L., Science 220 (1983), 868–871.
62. [62] Miyoshi, I., Taguchi, H., Kobonishi, I., Yoshimoto, S., Ohtsuki, Y., Shiraishi, Y., Akagi, T., Gann. Monogr. 28 (1982), 219–228.